Prev Close | 18.62 |
Day Low/High | 18.30 / 19.84 |
52 Wk Low/High | 8.50 / 25.46 |
Prev Close | 18.62 |
Day Low/High | 18.30 / 19.84 |
52 Wk Low/High | 8.50 / 25.46 |
Exchange | NASDAQ |
Shares Outstanding | 61.65B |
Market Cap | 1.15B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Omeros Corp. and Eyenovia Inc. were the recipients of positive news this week.
I think the market is getting at least a little ahead of itself.
This covered call strategy is an effective way to navigate an overbought market.
With lockdowns ending and life as we knew it resuming to some extent, these three stocks should benefit.
Dynavax Technologies and Omeros Corp. have tested shareholders' patience over time and again are at inflection points.
The trio of BioDelivery Sciences, Omeros and TG Therapeutics looks well-positioned to capitalize on their potential in the New Year.
Both these names reported third-quarter results last week.
Omeros Corp. and EyePoint Pharmaceuticals each have promising treatments that could send their shares skyward.
These small biotech concerns are undervalued.
It's a decent start to the trading day as all the major indices are slightly in the green. We are seeing a lot of small biotech stocks I have profiled in these pages rallying on news. Let's start with T2 Biosystems . It is up 25% today as it was awa...
The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.
As always it was good to sit in for Doug Kass over the past two trading sessions. Equities lost some traction toward the end of the day. The Dow and S&P 500 closed with OK gains while the NASDAQ was down slightly. Biotech was not the place to be tod...
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
Several biotech names held up well or even had solid advances during last week's broad market selloff.
Achaogen and Omeros both rose as the Dow was losing 724 points.
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
Favorable quarterly results and FDA drug approvals should help lift these five names.
Favorable quarterly results and FDA drug approvals should help lift these five names.
The housing market will continue to improve over the next few years due to pent up demand.
Diversification is absolutely critical when investing in this sector.
These names are building a sound foundation for growth.
Several firms hiked price targets on Portola into the $70s this week.
Several firms hiked price targets on Portola into the $70s this week.
The sector decisively has pushed through upward resistance levels in place for many months.
Looks like the grocery sector is going to be a theme for this Friday. In the story of the day, and maybe of the week, Amazon has announced it will buy organic food pioneer Whole Foods for $42 a share in an all-cash transaction. Walmart is down 5% i...
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
The indices are holding key support, but this isn't translating into any real momentum.
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
The market has strengthened considerably since our last update, with all the major indices sporting solid gains across the board. Oil is also up 1% on the day. Restaurant stocks are having a good day after solid earnings reports from Yum Brands and...
Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...